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Impairment in instrumental activities of daily living (IADL) is an early clinical feature of Alzheimer’s
disease (AD). The neurobiology underlying IADL disruptions is still unclear. We aimed to investigate the
relationship between IADL functioning and cortical atrophy across the AD spectrum. We selected 162
memory-clinic subjects with subjective cognitive decline (n ¼ 49), mild cognitive impairment (n ¼ 26) or
AD dementia (n ¼ 87), and an available structural MRI acquired at 3.0 Tesla and Amsterdam IADL
Questionnaire (A-IADL-Q) assessment. We used linear regression correcting for age, sex, education,
vascular injuries, and total intracranial volume to investigate the association between gray matter vol-
ume and A-IADL-Q score, and voxel-based morphometry to investigate whether any associations were
speciﬁc for distinct regions. Less gray matter volume was associated with lower A-IADL-Q scores (b ¼
0.346, 95% CI ¼ [0.185-0.507], p < 0.001), speciﬁcally in cortical regions covering the medial temporal
lobes, cingulate cortex, and precuneus (all p(familywise errorecorrected) < 0.05). Results were similar
when repeating the analyses in amyloid-positive subjects (n ¼ 78). Our ﬁndings illustrate that the A-
IADL-Q detects functional impairment related to AD-speciﬁc neurodegeneration.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The clinical course of dementia is characterized by progressive
cognitive decline and increased interference in daily living
(American Psychiatric Association, 2013). The ﬁrst reported prob-
lems in everyday life typically involve the more cognitively complex
activities such as cooking, managing ﬁnances, and operating devices
(Lawton and Brody, 1969), usually referred to as “instrumental ac-
tivities of daily living” (IADL). Alzheimer’s disease (AD) is the most
common cause of dementia worldwide (Scheltens et al., 2016).
Several studies have shown that IADL impairment can already be
detected in individuals with subjective cognitive decline (SCD) and
mild cognitive impairment (MCI) (Jutten et al., 2017; Kaur et al.,
2016; Reppermund et al., 2013) which are considered to be at riskimer Center Amsterdam, P.O.
31 20 444 0816; fax: þ31 20
Inc. This is an open access article uand prodromal stages of AD (Albert et al., 2011; Jessen et al., 2014).
IADL performance has been related to quality of life of both patients
and their caregivers (Giebel et al., 2015), making it an important
assessment in clinical practice. In the context of intervention studies
and disease-modifying treatments, IADL assessment is often used to
evaluate treatment effects on everyday cognition because improve-
ment on a clinical meaningful measure is required for approval ac-
cording to the Food and Drug Administration guidelines (Food and
Drug Administration, 2018). In summary, IADL functioning is
considered a highly relevant outcome in both AD research and
clinical practice. Still, it remains unclear to what extent IADL func-
tioning is related to neurodegenerative processes of AD.
Cortical atrophy is one of the hallmark neuronal injury char-
acteristics of AD (Ewers et al., 2011; Jack et al., 1997). It is one of the
strongest neural correlates of cognitive functioning across the AD
clinical spectrum, with hippocampal atrophy showing the most
robust correlations with decline on memory tests (Di Paola et al.,
2007; Fox et al., 1999; Petersen et al., 2000; Smits et al., 2014).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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variance in an individual’s functional status (Royall et al., 2007),
and so it remains unclear to what extent atrophy is related to
complex everyday life functions. Previous studies addressing this
topic found that worse performance of everyday activities was
related to global brain atrophy and atrophy in a priori deﬁned re-
gions such as the hippocampi (Cahn-Weiner et al., 2007; Farias
et al., 2013; Marshall et al., 2014; Okonkwo et al., 2010; Rueda
et al., 2015). However, studies using unbiased volumetric imag-
ing techniques have shown that IADL-related atrophy may not be
conﬁned to the hippocampal formation, but might involve much
more widespread anatomical areas (Vasconcelos et al., 2011;
Vidoni et al., 2010). However, those studies studied relatively
small groups that did not include prodromal stages of AD
(Vasconcelos et al., 2011), or used functional measures that focus
less on modern everyday life activities (Vidoni et al., 2010) and
therefore may be less relevant for the current elderly population
(Jekel et al., 2015; Sikkes et al., 2009). Therefore, the relation be-
tween atrophy and more complex activities of daily living across
the AD spectrum warrants further investigation.
We recently developed a modern scale to assess everyday
functioning in an early-onset AD population: the Amsterdam IADL
Questionnaire (A-IADL-Q). The A-IADL-Q is an informant-based
measure and was developed with input from patients, caregivers,
and health care professionals (Sikkes et al., 2012). It assesses the
performance of a broad range of speciﬁc everyday activities,
includingmodern ones such as the use of technological devices. The
A-IADL-Q has good content validity, good reliability, adequate
diagnostic accuracy, and was found to be sensitive to changes over
time in incipient dementia (Koster et al., 2015; Sikkes et al., 2013b).
It was validated against other clinical measures for global cognition
and quality of life (Sikkes et al., 2013a), but so far it had not been
compared with a biological marker of neurodegeneration.
The aim of this study was to investigate the relationship be-
tween IADL performance as measured with the A-IADL-Q and
cortical atrophy in a memory-clinic population covering the
clinical spectrum from SCD to AD dementia. Using exploratory
voxel-based morphometry (VBM), we investigated whether worse
IADL performance was related to less global gray matter volume,
and whether such associations were speciﬁc for distinct brain
regions.
2. Methods
2.1. Study population
We selected 162 participants from the memory-clinicebased
Amsterdam Dementia Cohort (van der Flier, 2018) when they had
(1) a diagnosis of SCD, MCI, or AD dementia; (2) availability of a
structural brain MRI scan on a 3.0 Tesla scanner; and (3) a
completed A-IADL-Q assessment. All participants had undergone a
complete diagnostic workup in the VU University Medical Center
(VUmc) Alzheimer Center between January 2010 and September
2015. This included a diagnostic interview, medical history, physical
and neurological examination, neuropsychological assessment,
laboratory tests, and structural brain imaging. During this visit, the
subject’s study partner (mostly a spouse, child or close relative)
completed the A-IADL-Q independently on an iPad. Reliability of
the study partner was based on the clinician’s impression during
the diagnostic interview. Diagnoses were made in a multidisci-
plinary consensus meeting according to the clinical criteria for MCI,
possible or probable AD (Albert et al., 2011; McKhann et al., 2011),
and research criteria for SCD (Jessen et al., 2014). Attendees of this
meeting were unaware of the subject’s A-IADL-Q score and the
diagnosis was therefore made independently of the A-IADL-Q.Themedical-ethical committee of the VUmc approved the study.
All participants and study partners gave written informed consent
to use their clinical data for research.
2.2. Amsterdam IADL Questionnaire
IADL functioning was measured with the A-IADL-Q: an
informant-based scale with 70 items covering a broad range of
cognitive IADL (Sikkes et al., 2012, 2013a,b). Compared with exist-
ing IADL instruments, the A-IADL-Q includes more complex IADL
activities that are prone to decline in early stages of dementia, as
well as more modern activities that are nowadays relevant in
everyday life (Sikkes et al., 2009). Overall, the content of the items
can be described as household activities, administration, work,
computer use, leisure time, appliances, transport, and other activ-
ities. Example items include “using amobile phone”, “using e-mail,”
and “using electronic banking”. The A-IADL-Q is computerized and
has an adaptive approach as the items are tailored to individual
responses, resulting in a minimum of 47 and a maximum of 70
items for each respondent. Difﬁculty in performance is rated on a 5-
point Likert scale, ranging from “no difﬁculty in performing this
task” to “no longer able to perform this task”. Scoring is based on
item response theory (IRT): a paradigm linking responses to a test
battery to an underlying construct (or latent trait) (Embretson and
Reise, 2013). For the A-IADL-Q, the construct underlying the items
reﬂects “IADL functioning” (Jutten et al., 2017; Sikkes et al., 2013a).
An important advantage of the IRT scoring method is that one’s
latent trait score can be estimated from any set of items resulting
from the A-IADL-Q. Therefore, IRT is able to handle missing data
that may result from the adaptive approach. To ease interpretation
of the scores, IRT scores are converted to normally distributed T-
scores (M ¼ 50, SD ¼ 10), with lower scores reﬂecting poorer IADL
functioning.
2.3. MRI acquisition and preprocessing
All participants had undergone a high resolution structural
whole-brain MRI-scan on a 3.0 Tesla scanner (SignaHDxt; GE
Healthcare, Milwaukee, WI, USA). T1-weighted 3D gradient echo
sequences were obtained with the following acquisition parame-
ters: repetition time 7.8 ms, echo time 3.0 ms, ﬂip angle 12; 176
sagittal slices, ﬁeld of view 240 mm2; slice thickness 1 mm; voxel
size 0.94 0.94 1 mm3. A 3D ﬂuid attenuation inversion recovery
sequence was obtained for the visual rating of white matter
hyperintensities (WMH) and lacunes. The quality of the scans was
checked by an experienced neuroradiologist.
Preprocessing of the 3D T1 images was performed using the
Statistical Parametric Mapping 12 (SPM12) software (Wellcome
Trust Centre for Neuroimaging, University College London, UK)
running in MATLAB 2011a (MathWorks Inc, Natick, MA, USA).
Before preprocessing, the origin in each scan was manually set to
the anterior commissure. Scans were segmented into gray matter
(GM), white matter (WM), and cerebrospinal ﬂuid (CSF). Next, to
account for atrophy in the sample, we created a sample-speciﬁc
Diffeomorphic Anatomical Registration Through Exponentiated
Lie Algebra (Dartel) template (Ashburner and Friston, 2000) of the
Dartel imported graymatter segmentations. Finally, the graymatter
segmentations werewarped to this Dartel template and normalized
to Montreal Neurological Institute space with a Gaussian ﬁlter of 8-
mm full width at half maximum. RJJ visually checked the quality of
all individual segmentations. Total GM (i.e., the sum of all GM
voxels) and total intracranial volume (TIV; i.e., GM þ WM þ CSF
volume) were derived from the segmented images in native space
(units in liter). The smoothed, normalized, and modulated images
were used for the VBM analyses.
R.J. Jutten et al. / Neurobiology of Aging 75 (2019) 109e116 1112.4. Covariates
Educational level was scored according to the Dutch Verhage
classiﬁcation system, ranging from 1 (low education, i.e., not
ﬁnished primary school) to 7 (high education, i.e., a master’s or
doctor’s degree). To correct our analyses for markers of vascular
injury, we also included information on WMH and total number of
lacunes, which were scored by a trained neuroradiologist. Severity
ofWMHwas rated using the visual Fazekas scale ranging from 0 (no
WMH) to 3 (severe WMH).
2.5. Statistical analyses
Statistical analyses were performed using SPSS version 22.0
and SPM12. Signiﬁcance level was set at p < 0.05, unless
mentioned otherwise. Demographic differences between the
diagnostic groups were investigated with one-way analyses of
variance followed by Hochberg’s post hoc tests for continuous
data measured on interval level, and a Kruskal-Wallis test for
ordinal variables or as nonparametric alternative. Sex differences
between groups were investigated using c2 tests. We investigated
the association between normalized gray matter volume (inde-
pendent, deﬁned as total GM divided by TIV) and A-IADL-Q score
(dependent) in the total group using a linear regression analysis.
We also investigated a second model including age, sex, educa-
tion, and WMH as covariates by entering them to the regression
model based on the strength of their correlation with A-IADL-Q
score. We reported the standardized regression coefﬁcients
including standard error and 95% conﬁdence intervals. To explore
the relation between IADL functioning and cortical atrophy within
each group, we repeated these analyses after stratifying for
diagnostic group (i.e., SCD, MCI, or AD dementia). We also
repeated the analyses in a subsample of individuals with
abnormal amyloid to assess whether ﬁndings are speciﬁc for
biomarker-conﬁrmed AD. CSF data that had been obtained during
the same day as the MRI scan was available for 78% of the subjects
(n ¼ 124). Amyloid positivity was determined based on amyloid
beta 1-42 levels, with a cutoff of 813 pg/mL as deﬁned for the
Amsterdam Dementia Cohort (Tijms et al., 2018).
In case a signiﬁcant association between normalized gray
matter volume and A-IADL-Q score was found, we used voxel-
based morphometry (VBM) (Ashburner and Friston, 2000) ana-
lyses to identify whether any such association was speciﬁc for
distinct regions. The voxelwise association between gray matter
volume and A-IADL-Q score was determined using multiple linear
regression in SPM12, with A-IADL-Q score as primary predictor
and age, sex, education, and TIV entered as covariates. To limit the
analysis to areas of gray matter, an absolute threshold maskingTable 1
Demographic and clinical characteristics
Total group (N ¼ 160) SCD (n ¼ 49) MCI (n ¼ 25)
Age 65.4 (7.9) 62.3 (8.2) 69.8 (6.2)
Female (%) 70 (43.8%) 16 (32.7%) 8 (32%)
Education 5.0 (1.3) 4.9 (1.4) 5.2 (1.6)
MMSE score 23.6 (4.9) 27.3 (2.3) 26.6 (2.9)
A-IADL-Q score 52.4 (9.5) 58.6 (8.3) 54.7 (6.9)
Normalized gray
matter volume
0.406 (0.04) 0.442 (0.03) 0.402 (0.04)
Fazekas score 1 (0e1) 1 (0e1) 1 (0e2)
Lacunes 0 (0e0) 0 (0e0) 0 (0e0)
Data for age, sex, education, MMSE, A-IADL-Q, and normalized gray matter volume (un
lacunes are presented as median (Q1-Q3).
Key: SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, probable A
State Examination; N/A, not applicable as no group differences were detected.
a p < 0.05 according to Hochberg post hoc tests.
b Tested using one-way ANOVA, c2 or Kruskal-Wallis test if appropriate.was set to only include voxels with gray matter probabilities
exceeding 0.10. For each analysis, this resulted in an expected
cluster size as indicated by SPM, which we used as minimum
extent threshold to select signiﬁcant clusters or peaks for that
speciﬁc analysis. Analyses in the total group were corrected for
multiple comparisons using the familywise error (FWE) method
(signiﬁcance level of p < 0.05). We repeated the analyses stratiﬁed
for diagnostic group, and we also explored within group associa-
tions in the amyloid-positive group. These exploratory analyses
were initially uncorrected for multiple comparisons, with a sig-
niﬁcance level set at p < 0.001. If signiﬁcant clusters were iden-
tiﬁed, we additionally investigated whether these would survive
the FWE-correction. We reported the location of peak voxels
within signiﬁcant clusters with reference to the Montreal Neuro-
logical Institute standard space and corresponding brain regions
according to the anatomical automatic labeling (AAL) atlas
(Tzourio-Mazoyer et al., 2002).
3. Results
After preprocessing, we identiﬁed 2 outliers in the gray matter
and A-IADL-Q distributions. The ﬁrst was due to erroneous seg-
mentation and the second appeared to have a cognitively impaired
informant leading to an unreliable A-IADL-Q assessment. As these
cases were considered measurement errors, we excluded them
from our further analyses. These participants did not differ from the
remaining group in terms of demographics and clinical
characteristics.
Table 1 shows the demographic and clinical characteristics of
the remaining total group (N ¼ 160). The SCD group (n ¼ 49,
62.3 years 8.2) was signiﬁcantly younger than the MCI group (n ¼
25, 69.8 years6.2, p¼ 0.001) and AD group (n¼ 86, 66 years7.5,
p¼ 0.021). Total MMSE scores were signiﬁcantly higher in SCD (27.3
 2.3) compared with AD (20.4  4.5, p < 0.001) as well as for MCI
(26.6  2.9) compared with AD (p < 0.001). IADL scores were lower
in the AD group (48.1  8.6) compared with both the SCD group
(58.6  8.3, p < 0.001) and the MCI group (54.7  6.9, p ¼ 0.002).
Participants with SCD had higher normalized gray matter volumes
(0.442 0.03) compared withMCI (0.402 0.04, p< 0.001) and AD
(0.388  0.03, p < 0.001). Fazekas scores and amount of lacunes did
not signiﬁcantly differ between the groups. In fact, lacunes were
absent in almost all participants and we therefore did not include
this variable in our regression analyses.
3.1. Gray matter volume and IADL functioning
Across the clinical spectrum, lower normalized gray matter
volume was associated with lower A-IADL-Q scores indicatingAD dementia (n ¼ 86) p-valueb Signiﬁcant pairwise differencesa
66.0 (7.5) <0.001 SCD < MCI, SCD < AD
46 (53.5%) 0.023 N/A
5.0 (1.1) 0.626 N/A
20.6 (4.5) <0.001 SCD > AD, MCI > AD
48.1 (8.6) <0.001 SCD > AD, MCI > AD
0.388 (0.03) <0.001 SCD > MCI, SCD > AD
1 (0e1) 0.124 N/A
0 (0e0) 0.073 N/A
it in liters) are presented as mean (standard deviation); data for Fazekas score and
lzheimer’s disease; A-IADL-Q, Amsterdam IADL Questionnaire; MMSE, Mini-Mental
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0.001; Fig. 1, Table 2). This association remained signiﬁcant after
correcting for age, sex, education, and WMH (corrected b ¼ 0.346,
95% CI ¼ [0.185e0.507], p < 0.001, Table 2). When we stratiﬁed
analyses according to diagnostic group, we observed that lower
normalized graymatter volumewas associated with worse A-IADL-
Q scores at a trend level in the AD group after correcting for age, sex,
WMH, and education (p ¼ 0.076, Table 2). We found no signiﬁcant
associations within the SCD and MCI groups.
Stratiﬁcation on amyloid status resulted in 78 amyloid-positive
and 46 amyloid-negative subjects (see Table 3). Age (M ¼ 66.4,
SD ¼ 7.1), education level (M ¼ 5.0, SD ¼ 1.3), and sex (50% female)
did not signiﬁcantly differ between the amyloid-positive and the
amyloid-negative group. Scores on the MMSE (M ¼ 21.9, SD ¼ 4.8),
A-IADL-Q (M ¼ 49.8, SD ¼ 8.5) and GMV (M ¼ 0.396, SD ¼ 0.03)
were all lower for the amyloid-positive group (all p-values <0.001,
Table 3). Regression analyses in the amyloid-positive group yielded
comparable results as in the total sample, in which lower normal-
ized gray matter volume was associated with a lower A-IADL-Q
score (b ¼ 0.234, 95% CI ¼ [0.011e0.456], p ¼ 0.04). This association
remained signiﬁcant after correcting for age, sex, education, and
WMH (corrected b ¼ 0.249, 95% CI ¼ [0.021e0.478], p ¼ 0.03). We
did not ﬁnd any signiﬁcant associations in the amyloid-negative
group. Further repeating analyses for the amyloid-positive AD de-
mentia group (n ¼ 67) showed similar effects as in the total AD
dementia group; however this effect did not reach statistical sig-
niﬁcance (corrected b ¼ 0.181, p ¼ 0.16).
3.2. Voxelwise association between gray matter and IADL
functioning
The VBM analysis in the total group showed 10 clusters where
less graymatter volumewas related to a lower A-IADL-Q score (all pFig. 1. Scatterplot displaying the relation between normalized gray matter volume (correct
Abbreviations: A-IADL-Q, Amsterdam IADL Questionnaire; AD, Alzheimer’s disease.(FWE-corrected) < 0.05, Fig. 2, Table 4). The largest clusters were
located bilaterally in the cingulum, medial temporal lobes, and
hippocampi, and we also found associations in the left precuneus,
inferior parietal cortex, and angular gyrus (Table 4).
Because regression analyses stratiﬁed for diagnostic group
showed a trend toward a relation between A-IADL-Q score and gray
matter volume in the AD group, we only repeated the VBM analyses
in this subgroup. The VBM showed no signiﬁcant associations on
cluster level, but several peaks of gray matter were signiﬁcantly
associated with IADL functioning (all p(unc) < 0.001). These were
located in the left and right medial temporal lobes, left and right
thalamus, and around the left fusiform gyrus and parahippocampal
gyrus (Fig. 3, Table 5).
VBM analyses in the amyloid-positive group showed 2 signiﬁ-
cant associations on cluster level in the left hippocampus and
medial temporal lobe and several peaks bilaterally in the medial
temporal lobes, precuneus, and cingulum where IADL functioning
was related to gray matter volume (all p(unc) < 0.001). After cor-
recting for multiple comparisons, only 1 cluster located in the left
hippocampus survived the correction (p (FWE-corrected) < 0.05).
4. Discussion
We found that worse IADL functioning as measured with the A-
IADL-Q was related to less gray matter volume across the clinical
spectrum ranging from SCD to AD dementia. We demonstrated that
this relationship was independent of age, sex, education, and
markers for vascular injury. VBM indicated that associations be-
tween IADL and graymatter volumeweremostly speciﬁc for typical
AD brain regions, such as the medial temporal lobes including the
hippocampi and the cingulate cortex and associated areas including
the precuneus. After stratifying on clinical diagnosis, these associ-
ations were only apparent in the AD group and mostly localized ined for total intracranial volume) and A-IADL-Q score across the AD clinical spectrum.
Table 2
Standardized regression coefﬁcients for A-IADL-Q score, for the total group and after stratiﬁcation based on diagnostic group
Model Total group (N ¼ 160) SCD (n ¼ 49) MCI (n ¼ 25) AD (n ¼ 86)
b (SE) 95% CI p-
value
b (SE) 95% CI p-
value
b (SE) 95% CI p-
value
b (SE) 95% CI p-
value
1 nGMV 0.297 (0.08) 0.147 to 0.447 <0.001 0.088 (0.15) 0.381 to 0.204 0.546 0.329 (0.2) 0.736 to 0.079 0.109 0.184 (0.11) 0.03 to 0.397 0.091
2 nGMV 0.346 (0.08) 0.185 to 0.507 <0.001 0.142 (0.18) 0.501 to 0.217 0.43 0.364 (0.25) 0.892 to 0.164 0.166 0.202 (0.11) 0.02 to 0.425 0.076
Age 0.042 (0.09) 0.131 to 0.216 0.631 0.189 (0.18) 0.542 to 0.163 0.285 0.25 (0.22) 0.217 to 0.717 0.276 0.023 (0.13) 0.226 to 0.273 0.852
Sex 0.079 (0.08) 0.231 to 0.072 0.303 0.231 (0.15) 0.065 to 0.527 0.123 0.236 (0.19) 0.169 to 0.641 0.238 0.049 (0.12) 0.282 to 0.184 0.678
WMH 0.127 (0.08) 0.039 to 0.293 0.133 0.145 (0.16) 0.171 to 0.462 0.36 0.152 (0.18) 0.219 to 0.523 0.401 0.058 (0.13) 0.207 to 0.322 0.666
Edu 0.122 (0.08) 0.027 to 0.272 0.109 0.169 (0.15) 0.129 to 0.466 0.26 0.375 (0.19) 0.025 to 0.776 0.065 0.058 (0.11) 0.166 to 0.282 0.608
Key: b, standardized regression coefﬁcient; SE, standard error; SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, probable Alzheimer’s disease; A-IADL-Q,
Amsterdam IADL Questionnaire; nGMV, normalized gray matter volume; WMH, white matter hyperintensities (Fazekas score 0e3); Edu, education.
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positive subjects only, we again found that IADL functioning was
related to gray matter volume across the AD spectrum profoundly
in the left medial temporal lobes and precuneus. These ﬁndings
further suggest that the associations we found are speciﬁc for the
AD neurodegenerative process.
Our ﬁndings regarding overall graymatter volumes and IADL are
largely in line with previous studies reporting that more overall
cortical atrophy is associated with worse performance in activities
of daily living across the AD clinical spectrum (Cahn-Weiner et al.,
2007; Farias et al., 2013; Marshall et al., 2014; Okonkwo et al.,
2010). The present study further contributed to these previous
studies by also investigating this relationship speciﬁcally in in-
dividuals who were biomarker-positive for AD. It should be noted
that the associations we found were only moderately strong, which
is often seen in MRI studies associating global atrophy with clinical
measures (Schmand et al., 2014). This suggests that, besides the
degree of cortical atrophy, there are potentially other biological
factors or interindividual differences that contribute to the severity
of clinical symptoms such as IADL impairment.
VBM analyses in the total group demonstrated that associations
between graymatter volume and IADL functioning were speciﬁc for
anatomical regions that are known to be involved in the patho-
logical process of AD. Atrophy in the medial temporal lobes and
especially the hippocampus is a major hallmark of AD and has been
associated with IADL interference before (Cahn-Weiner et al., 2007;
Farias et al., 2013). We showed that regions outside the medial
temporal lobes were also associated with IADL functioning, such as
the cingulate cortex and the more posterior located precuneus and
temporal-parietal located angular gyrus. These areas are all part ofTable 3
Demographic and clinical characteristics after stratiﬁcation based on amyloid status
Amyloid positive
(n ¼ 78)
Amyloid negative
(n ¼ 46)
p-
valuea
Clinical diagnosis (SCD/
MCI/AD)
5/9/63 33/12/1 N/A
Age 66.4 (7.1) 63.6 (9.5) 0.067
Female (%) 39 (50%) 15 (32.6%) 0.059
Education 5.0 (1.3) 5.1 (1.4) 0.875
MMSE score 21.9 (4.8) 26.9 (3.1) <0.001
A-IADL-Q score 49.8 (8.5) 57.7 (8.2) <0.001
Normalized gray matter
volume
0.396 (0.03) 0.433 (0.04) <0.001
Fazekas score 1 (0e1) 1 (0e1) 0.621
Lacunes 0 (0e0) 0 (0e0) 0.224
Data for age, sex, education, MMSE, A-IADL-Q, and GMV are presented as mean
(standard deviation); data for Fazakas score and lacunes are presented as median
(Q1-Q3).
Key: SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, prob-
able Alzheimer’s disease; MMSE, Mini-Mental State Examination; A-IADL-Q,
Amsterdam IADL Questionnaire; N/A, not applicable.
a Tested using oneway ANOVA, Chi Square or Kruskal-Wallis test if appropriate.or closely connected with the posterior cingulate cortex (PCC), a
region that was found to be affected early in neurodegenerative
disorders and particularly in AD (Buckner et al., 2005; Leech and
Sharp, 2014). The PCC is assumed to play a key role during atten-
tion regulation and internally directed cognitive functions, which
are all involved in performing IADL. Recent studies using cerebral
metabolism have additionally shown that worse everyday func-
tioning is associated with brain dysfunction in posterior brain re-
gions including the PCC (Melrose et al., 2011; Roy et al., 2014). Other
functional neuroimaging studies also showed an association be-
tween IADL dysfunction and cerebral activity in parietal regions in
patients with AD, which largely overlaps with the regions identiﬁed
in our study (Nadkarni et al., 2012; Salmon et al., 2005).
It should be noted that we did not ﬁnd any associations between
IADL functioning and brain regions located more frontally in the
brain. This was somewhat unexpected because frontal regions are
known to be involved in executive functions (Schmand et al., 2014),
which are assumed to play an important role in successfully per-
forming IADL (Gold, 2012). However, our ﬁndings were in line with
the study of Cahn-Weiner et al. showing that, while both the
cognitive domains memory and executive functions were associ-
ated with decline in IADL, hippocampal volume was the only neu-
roimaging marker predicting these IADL changes (Cahn-Weiner
et al., 2007). Together with the ﬁndings from the present study,
this suggests that atrophy in memory-related brain structures plays
an important role in predicting one’s level of IADL performance.
The present study has some limitations to take into account.
These include the relatively small sample sizes of the SCD and
particularly the MCI group, which possibly led to a power problem
for detecting signiﬁcant associations within these groups. It should
also be noted that there was little variance in the gray matter vol-
umes and A-IADL-Q scores in the SCD group, which further reﬂects
their normal cognition and these ceiling effects are probably the
reason why no association between these measures was observed
in this subgroup. In addition, although both SCD and MCI are
considered to be at risk stages for developing AD dementia, we do
not know which of them will actually convert to AD dementia.
Longitudinal data on the A-IADL-Q is currently collected in a larger
clinical sample, and suggestions for future research include the use
of these data to investigate the association between gray matter
volume and IADL functioning in SCD or MCI participants who
eventually develop AD. This would also enable us to investigate
which speciﬁc brain regions are related to IADL changes over time
and may thereby be useful for predicting future decline in IADL
functioning.
Strengths of our study include the use of the A-IADL-Q to
measure everyday functioning. In constrast to other widely used
IADL scales, the A-IADL-Q is a well-validated and comprehensive
measure of everyday functioning, containing modern and relevant
IADL activities in early AD (Sikkes et al., 2009). Furthermore, the use
of VBM rather than regional analyses is a major strength of our
Fig. 2. Signiﬁcant clusters of regression gray matter volume and A-IADL-Q score across the AD clinical spectrum (T-statistic indicating the strength of association with lighter colors
representing stronger associations). Abbreviations: A-IADL-Q, Amsterdam IADL Questionnaire; AD, Alzheimer’s disease. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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comprehensiveness, and freedom from observer bias (Ashburner
and Friston, 2000). The use of this unbiased method in relating
atrophy to IADL functioning was a novel aspect of this study
because most previous studies on IADL and atrophy restricted theirTable 4
Regions of signiﬁcant gray matter volume associated with A-IADL-Q score across the AD
Cluster level Peak level
p(FWE-corr)a p(unc)b Number of voxels (k) p(FWE-corr)a p(unc)b T
<0.001 0.000 904 <0.001 <0.001 5
0.001 <0.001 5
0.036 <0.001 4
<0.001 0.005 438 0.001 <0.001 5
0.006 <0.001 5
<0.001 0.000 1843 0.002 <0.001 5
0.003 <0.001 5
0.007 <0.001 5
0.002 0.037 217 0.002 <0.001 5
0.021 <0.001 4
<0.001 0.006 414 0.005 <0.001 5
0.008 <0.001 5
0.018 <0.001 4
0.002 0.045 197 0.006 <0.001 5
0.023 <0.001 4
0.004 0.084 141 0.008 <0.001 5
0.008 0.162 89 0.014 <0.001 4
0.001 0.021 275 0.014 <0.001 4
0.026 <0.001 4
0.015 0.299 48 0.020 <0.001 4
Signiﬁcant clusters detected a p(FWE) < 0.05, cluster size k > 48.
Key: A-IADL-Q, Amsterdam IADL Questionnaire; MNI, Montreal neurological institute; A
a p(FWE-corr) ¼ Familywise error corrected p-value.
b p(unc) ¼ uncorrected p-value.analyses to only a few a priori deﬁned brain regions. Finally, the
additional analyses in the amyloid-positive group are an important
and novel aspect of this study, as it enabled us to further investigate
whether the relation between IADL and cortical atrophy was spe-
ciﬁc to AD pathology.clinical spectrum (N¼160)
Coordinates in MNI space (x, y, z) Brain region (AAL atlas)
-statistic
.76 4, 34, 45 Cingulum medial left
.55 6, 34, 36 Cingulum medial left
.66 2, 21, 34 Cingulum medial right
.60 2, 46, 4 Temporal medial left
.12 52, 45, 14 Temporal superior right
.45 33, 36, 4 Hippocampus left
.29 27, 12, 18 Hippocampus left
.09 32, 24, 12 Hippocampus left
.39 48, 56, 46 Parietal inferior left
.81 48, 68, 33 Angular gyrus left
.19 57, 15, 14 Temporal medial left
.04 50, 3, 32 Temporal inferior left
.85 54, 10, 22 Temporal medial left
.11 46, 18, 9 Temporal medial right
.78 51, 20, 2 Temporal superior right
.07 52, 60, 21 Temporal medial left
.92 8, 58, 21 Precuneus left
.92 30, 20, 16 Hippocampus right
.75 24, 32, 6 Parahippocampal gyrus right
.83 60, 38, 21 Temporal inferior left
AL, anatomical automatic labeling.
Fig. 3. Signiﬁcant peaks of regression between gray matter volume and A-IADL-Q score in the AD dementia group (T-statistic indicating the strength of association with lighter
colors representing stronger associations). Abbreviations: A-IADL-Q, Amsterdam IADL Questionnaire; AD, Alzheimer’s disease. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the Web version of this article.)
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detect problems in complex activities of daily living that are asso-
ciated with AD-speciﬁc neurodegeneration. Because IADL func-
tioning is the core clinical feature of dementia, and therefore
considered an important and clinically relevant construct in both
research and clinical practice, it should be carefully assessed using a
clinically meaningful metric reﬂecting the underlying pathology.
The present study provides further evidence that the A-IADL-Q is a
useful and valid instrument for these purposes.Table 5
Regions of signiﬁcant gray matter volume associated with A-IADL-Q score in the AD
dementia group (n¼86)
Cluster level Peak level Coordinates
in MNI space
(x, y, z)
Brain region
(AAL atlas)Number
of voxels (k)
p(unc)a T-
statistic
p(unc)a
370 0.083 4.63 <0.001 51, 48, 3 Temporal
medial right
3.92 <0.001 60, 46, 3 Temporal
medial right
147 0.260 3.80 <0.001 54, 12, 22 Temporal
medial left
3.59 <0.001 57, 16, 16 Temporal
medial left
548 0.039 3.73 <0.001 6, 18, 3 Thalamus left
3.30 <0.001 9, 20, 3 Thalamus right
265 0.136 3.69 <0.001 28, 18, 30 Fusiform
gyrus left
3.50 <0.001 21, 22, 24 Parahippocampal
left
Signiﬁcant peaks detected a p(unc) < 0.001, cluster size k > 124.
Key: A-IADL-Q, Amsterdam IADL Questionnaire; AD, Alzheimer’s disease; MNI,
Montreal neurological institute; AAL, anatomical automatic labeling.
a p(unc) ¼ uncorrected p-value.Disclosure
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